Abstract | PURPOSE: METHODS: We performed a 6-month, randomized, placebo-controlled, double-blind, crossover study in 100 patients who fulfilled the 1994 Centers for Disease Control and Prevention criteria for chronic fatigue syndrome. Between-group differences (placebo minus treatment) were calculated on a 10-point visual analog scale. RESULTS: Eighty patients completed the 3 months of placebo and 3 months of active treatment in a double-blind fashion. There were no differences between treatment and placebo in patient-reported fatigue (mean difference, 0.1; 95% confidence interval [CI]: -0.3 to 0.6) or well-being (mean difference, -0.4; 95% CI: -1.0 to 0.1). There were also no between-group differences in fatigue measured with the Abbreviated Fatigue Questionnaire, the Short Form-36 Mental or Physical Factor scores, or in the Hospital Anxiety and Depression Scale. CONCLUSION:
|
Authors | Daniel Blockmans, Philippe Persoons, Boudewijn Van Houdenhove, Marina Lejeune, Herman Bobbaers |
Journal | The American journal of medicine
(Am J Med)
Vol. 114
Issue 9
Pg. 736-41
(Jun 15 2003)
ISSN: 0002-9343 [Print] United States |
PMID | 12829200
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Anti-Inflammatory Agents
- Fludrocortisone
- Hydrocortisone
|
Topics |
- Adult
- Anti-Inflammatory Agents
(administration & dosage)
- Blood Pressure
- Cross-Over Studies
- Double-Blind Method
- Drug Therapy, Combination
- Fatigue Syndrome, Chronic
(drug therapy, pathology)
- Female
- Fludrocortisone
(administration & dosage)
- Humans
- Hydrocortisone
(administration & dosage)
- Male
- Pain Measurement
- Severity of Illness Index
- Surveys and Questionnaires
- Treatment Outcome
|